- Home
- IFRX vs PROP Comparison
IFRX vs PROP Comparison
Compare IFRX & PROP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IFRX | PROP |
|---|---|---|
| Founded | 2007 | 2001 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.0M | 102.6M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | IFRX | PROP |
|---|---|---|
| Price | $0.99 | $1.70 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $9.80 | $6.75 |
| AVG Volume (30 Days) | ★ 7.6M | 1.2M |
| Earning Date | 11-10-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $73,729.00 | ★ $166,577,000.00 |
| Revenue This Year | N/A | $3,967.26 |
| Revenue Next Year | $1,216.24 | $71.16 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.71 | $1.64 |
| 52 Week High | $2.82 | $10.58 |
Technical Indicators
Market Signals| Indicator | IFRX | PROP |
|---|---|---|
| Relative Strength Index (RSI) | 39.78 | 42.69 |
| Support Level | $1.15 | $1.65 |
| Resistance Level | $1.28 | $1.92 |
| Average True Range (ATR) | 0.14 | 0.11 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 1.21 | 23.64 |
Price Performance
Historical ComparisonAbout IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About PROP Prairie Operating Co.
Prairie Operating Co is a Houston-based independent energy company engaged in the development and acquisition of oil and natural gas resources in the United States. The Company's assets and operations are concentrated in the oil and liquids-rich regions of the Denver-Julesburg (DJ) Basin, with a focus on the Niobrara and Codell formations. The Company is committed to the responsible development of its oil and natural gas resources and is focused on maximizing returns through consistent growth, capital discipline, and sustainable cash flow generation.